Eliem Therapeutics Inc
NASDAQ:ELYM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.45
10.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Eliem Therapeutics Inc
Eliem Therapeutics Inc
Cash & Cash Equivalents
Eliem Therapeutics Inc
Cash & Cash Equivalents Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eliem Therapeutics Inc
NASDAQ:ELYM
|
Cash & Cash Equivalents
$93.1m
|
CAGR 3-Years
66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$13.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
20%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$2.8B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$4.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$1.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
See Also
What is Eliem Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
93.1m
USD
Based on the financial report for Dec 31, 2023, Eliem Therapeutics Inc's Cash & Cash Equivalents amounts to 93.1m USD.
What is Eliem Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
66%
Over the last year, the Cash & Cash Equivalents growth was 114%. The average annual Cash & Cash Equivalents growth rates for Eliem Therapeutics Inc have been 66% over the past three years .
You don't have any saved screeners yet
